AGL
agilon health, inc.0.6685
+0.0054+0.81%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
277.15MP/E (TTM)
-Basic EPS (TTM)
-0.78Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Agilon Health's Q2 revenue dipped 6% year-over-year to $1.4B, driven by a 3% drop in Medicare Advantage members to 497,500 amid 2024 partnership exits, while medical services expense climbed 5% y/y to $1.45B on higher per-member costs. This flipped medical margin negative at -$53M from +$106M last year, yielding an operating loss of $116M—up from $43M—and diluted EPS of -$0.25, confirmed against 414M shares with no anti-dilution flagged. YTD, revenue fell 5% to $2.9B but medical margin held positive at $75M, down 72% y/y, with net loss at $92M after $14M discontinued ops gain. Cash burned $67M in operations, leaving $171M in equivalents and $156M in marketable securities; $35M term debt matures 2026 at 8.3%, with $19M revolver availability and no covenant issues. Equity method CMS ACO investments added $5M income in Q2. Ongoing securities litigation poses disclosure risks.
8-K
CEO exits amid Q2 losses
Agilon Health's CEO Steven Sell resigned on July 29, 2025, prompting the board to appoint co-founder Ron Williams as Executive Chairman and form an Office of the Chairman with key executives to steer operations amid Q2 challenges. Total revenues fell 6% to $1.4 billion, with Medicare Advantage membership dipping to 498,000 and medical margin swinging to a $53 million loss from $106 million profit, hit by $85 million in risk adjustment shortfalls and prior period developments. The company suspended 2025 guidance, citing leadership flux and market headwinds, yet eyes 2026 gains through execution tweaks. Leadership voids test stability.
8-K
Annual meeting elects directors
Agilon Health's stockholders, at the May 28, 2025 annual meeting, elected Silvana Battaglia and Sharad Mansukani, M.D., as Class I directors until 2028, with Battaglia securing strong support while Mansukani faced notable opposition. They ratified Ernst & Young LLP as auditors for 2025 and approved executive compensation on an advisory basis. Board refreshment bolsters governance amid healthcare shifts.
10-Q
Q1 FY2025 results
Agilon health swung to a net income of $12.1 million in Q1 FY2025 ended March 31, 2025, up from a $6.0 million loss a year earlier, fueled by $14.0 million in discontinued operations gains from Hawaii asset sales while continuing operations posted a $1.9 million loss. Total revenues dipped 4% year-over-year to $1.53 billion amid a 6% drop in Medicare Advantage members to 490,700, yet medical margin held at $128.0 million (derived) with gross margin contracting to 3.3% from 4.7% on tighter cost controls. Operating cash flow improved to a $32.0 million use from $47.8 million, with free cash flow at negative $43.9 million (derived) after $10.9 million in capex; quarter-end cash and equivalents stood at $138.6 million, bolstered by $230.1 million in marketable securities, while $35.0 million term debt matures in 2026 at 8.3% with $36.1 million revolver availability under compliant covenants. Equity method investments in CMS ACO Models added $12.7 million in income, up 123% year-over-year. Membership churn lingers as a risk.
IPO
Website
Employees
Sector
Industry
AAGH
America Great Health
0.00+0.00
ADUS
Addus HomeCare Corporation
113.49-1.65
ALHC
Alignment Healthcare, Inc.
20.03-0.08
ASTH
Astrana Health Inc.
22.31+0.01
EHSI
Elite Health Systems, Inc.
1.31-0.14
INNV
InnovAge Holding Corp.
5.55-0.27
LWSCF
Sienna Sr Living Inc.
14.66+0.02
PIII
P3 Health Partners Inc.
4.59-0.36
PNTG
The Pennant Group, Inc.
29.73+0.00
SNDA
Sonida Senior Living, Inc.
31.53-0.06